Skip to main content

Table 1 Patient and tumour characteristics

From: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer

  All patients (n = 1269) Patients without molecular testa (n = 789) Patients with at least one molecular testa (n = 480)
Age (years, SD) 71.9 ± 11.8 74.4 ± 11.3 67.8 ± 11.4
Sex
 Women 578 (45.5%) 356 (45.1%) 222 (46.3%)
 Men 691 (54.5%) 433 (54.9%) 258 (53.8%)
Site of the primary tumour
 Rectum 309 (24.4%) 220 (28.0%) 89 (18.8%)
 Right colon 437 (34.4%) 268 (34.0%) 169 (35.0%)
 Left colon 523 (41.2%) 301 (38.0%) 222 (46.3%)
TNM stage
 Stage I 219 (17.3%) 194 (24.6%) 25 (5.2%)
 Stage II 380 (29.9%) 265 (33.6%) 115 (24.0%)
 Stage III 380 (29.9%) 232 (29.4%) 148 (30.8%)
 Stage IV 290 (22.8%) 98 (12.4%) 192 (40.0%)
Tumour grade (MD = 173)
 Well 436 (39.8%) 250 (37.7%) 186 (43.3%)
 Moderate 576 (52.5%) 369 (55.4%) 207 (47.9%)
 Poor 84 (7.7%) 46 (6.9%) 38 (8.8%)
Geographical area of primary treatment (MD = 4)
 Charente-Maritime 392 (31.0%) 286 (36.4%) 106 (22.1%)
 Charente 226 (17.9%) 171 (21.6%) 55 (11.5%)
 Deux-Sèvres 227 (17.9%) 110 (14.1%) 117 (24.4%)
 Vienne 301 (23.8%) 137 (17.4%) 164 (34.2%)
 Outside the region 119 (9.4%) 82 (10.4%) 37 (7.7%)
Status of the center (MD = 4)
 Public Hospital 551 (43.5%) 381 (48.6%) 170 (35.5%)
 Private hospital 512 (40.5%) 292 (37.2%) 220 (45.7%)
 University hospital 202 (16.0%) 112 (14.3%) 90 (18.8%)
  1. MD missing data, SD standard deviation
  2. aMolecular test defined as KRAS, BRAF and/or MSI testing